166880-01-9

Upstream product

• 78-39-7 Triethyl orthoacetate 
• 33671-41-9 5-(4-chloro-phenyl)-6,7-dimethyl-1,3-dihydro-thieno[2,3-e][1,4]diazepin-2-one 
• 54861-99-3 glycine 3-(4-chloro-benzoyl)-4,5-dimethyl-thiophen-2-ylamide 
• 204587-29-1 C₁₅H₁₃Cl₂NO₂S 
• 50508-66-2 (2-amino-4,5-dimethylthiophen-3-yl)(4-chlorophenyl)methanone 
• 4640-66-8 p-chlorobenzoylacetonitrile 

Downstream Products

• 1268524-70-4 (S)-tert-butyl 2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetate 
• 202592-23-2 (S)-[4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl]acetic acid 
• 916493-55-5 4-(4-methylaminophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine 

Relevant academic research and scientific papers

THIENODIAZEPINE DERIVATIVES AND APPLICATION THEREOF

The present invention relates to a class of thienodiazepine derivatives and an application thereof in the preparation of a drug for the treatment of diseases associated with bromodomain and extra-terminal (BET) Bromodomain inhibitors. Specifically, the present invention relates to compounds represented by formulas (I) and (II), as well as pharmaceutically acceptable salts thereof.

THIENOTRIAZOLODIAZEPINE COMPOUNDS AND MEDICINAL USES THEREOF

Thienotriazolodiazepine compounds of the formula (1) wherein each symbol is as defined in the specification, pharmaceutically acceptable salts thereof or hydrates thereof, and pharmaceutical agents containing this compound, a pharmaceutically acceptable s

Thienotriazolodiazepine compound and pharmaceutical use thereof

N-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno ?3,2-f!?1,2,4!triazolo?4,3-a!?1,4!diazepin-6-yl )-N'- (2-methoxyphenyl)urea, optical isomers thereof and pharmaceutically acceptable salts thereof. The compounds of the present invention strongly and selecti